Document is current
Any future updates will be listed below
-
Authors
Hegde, Samarth
Giotti, Bruno
Soong, Brian Y. https://orcid.org/0000-0003-4647-7704
Halasz, Laszlo
Le Berichel, Jessica
Schaefer, Maximilian M. https://orcid.org/0000-0002-6038-7847
Kloeckner, Benoit
Mattiuz, Raphaël https://orcid.org/0000-0002-3292-1635
Park, Matthew D.
Magen, Assaf
Marks, Adam
Belabed, Meriem
Hamon, Pauline https://orcid.org/0000-0002-6776-1635
Chin, Theodore
Troncoso, Leanna https://orcid.org/0000-0003-2529-9267
Lee, Juliana J.
Fan, Kaili
Ahimovic, Dughan https://orcid.org/0000-0002-5849-335X
Bale, Michael J.
Nie, Kai
Chung, Grace https://orcid.org/0000-0002-7101-6865
D’souza, Darwin
Angeliadis, Krista
Kim-Schulze, Seunghee https://orcid.org/0000-0003-0192-4400
Flores, Raja M.
Kaufman, Andrew J.
Ginhoux, Florent
Buenrostro, Jason D.
Josefowicz, Steven Z. https://orcid.org/0000-0001-7453-779X
Tsankov, Alexander M. https://orcid.org/0000-0002-7955-4414
Marron, Thomas U. https://orcid.org/0000-0001-5903-8191
Ma, Sai https://orcid.org/0000-0002-9785-7929
Brown, Brian D. https://orcid.org/0000-0002-3670-8778
Merad, Miriam https://orcid.org/0000-0002-4481-7827
- License Information
-
More Information
Article History
Received: 17 June 2024
Accepted: 5 August 2025
First Online: 10 September 2025
Competing interests
: M.M. serves on the scientific advisory board and holds stock from Compugen Inc., Dynavax Inc., Innate Pharma Inc., Morphic Therapeutics, Asher Bio Inc., Dren Bio Inc., Nirogy Inc., Genenta Inc., Oncoresponse, Inc. and Owkin Inc. M.M. also serves on the ad hoc scientific advisory board of DBV Technologies Inc. and Genentech Inc., and on the foundation advisory board of Breakthrough Cancer. M.M. receives funding for contracted research from Genentech, Regeneron and Boehringer Ingelheim. T.U.M. has served on advisory and/or data safety monitoring boards for Rockefeller University, Regeneron Pharmaceuticals, Abbvie, Bristol-Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, Glenmark, Simcere, Surface, G1 Therapeutics, NGMbio, DBV Technologies, Arcus and Astellas, and receives contracted grants from Regeneron, Bristol-Myers Squibb, Merck and Boehringer Ingelheim. The above interests are not directly relevant to this manuscript. The remaining authors declare no competing interests.
